Research programme: anti-midkine antibodies - Cellmid

Drug Profile

Research programme: anti-midkine antibodies - Cellmid

Alternative Names: CAB 101; CAB 102; Hu91- Cellmid; IP10; IP13; IP14; IP9

Latest Information Update: 13 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellmid
  • Class Monoclonal antibodies
  • Mechanism of Action MDK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 13 Jul 2016 Preclinical development is ongoing in Australia
  • 02 Feb 2010 This programme is available for licensing (http://www.cellmid.com.au)
  • 02 Feb 2010 Preclinical trials in Cancer in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top